Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical
Mehrdad Hashemi1,2, Asal Abolghasemi Fard1, Bita Pakshad1
1Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Abstract:
Lung cancer (LC) is one of the most common causes of cancer-related death worldwide. It has been demonstrated that the prognosis of current drug treatments is affected by a variety of factors, including late stage, tumor recurrence, inaccessibility to appropriate treatments, and, most importantly, chemotherapy resistance. Non-coding RNAs (ncRNAs) contribute to tumor development, with some acting as tumor suppressors and others as oncogenes. The phosphoinositide 3-kinase (PI3Ks)/AKT serine/threonine kinase pathway is one of the most important common targets of ncRNAs in cancer, which is widely applied to modulate the cell cycle and a variety of biological processes, including cell growth, mobility survival, metabolic activity, and protein production. Discovering the biology of ncRNA-PI3K/AKT signaling may lead to advances in cancer diagnosis and treatment. As a result, we investigated the expression and role of PI3K/AKT-related ncRNAs in clinical characteristics of lung cancer, as well as their functions as potential biomarkers in lung cancer diagnosis, prognosis, and treatment.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
lncRNA - Long Non-coding RNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
piRNA - Piwi-interacting RNAs
Experimental RNAi
Abnormal Proliferation


